Cargando…
Gene Therapy and Chronic Pain
Chronic, unremitting pain is perhaps the most common reason that patients seek medical care. In general, conservative techniques, such as medical management, are implemented as first-line therapy. Local anesthesia and lytic procedures, followed by interventional techniques, such as dorsal column sti...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
TheScientificWorldJOURNAL
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917261/ https://www.ncbi.nlm.nih.gov/pubmed/16951899 http://dx.doi.org/10.1100/tsw.2006.197 |
_version_ | 1783317168942743552 |
---|---|
author | Cope, Doris K. Lariviere, William R. |
author_facet | Cope, Doris K. Lariviere, William R. |
author_sort | Cope, Doris K. |
collection | PubMed |
description | Chronic, unremitting pain is perhaps the most common reason that patients seek medical care. In general, conservative techniques, such as medical management, are implemented as first-line therapy. Local anesthesia and lytic procedures, followed by interventional techniques, such as dorsal column stimulation and intrathecal drug delivery systems, are second-line therapies. However, for refractory and severe pain, which is not adequately controlled by other modes of therapy, new emerging options, including molecular or gene therapy, may become more widely utilized as experimental results are translated into clinical options. |
format | Online Article Text |
id | pubmed-5917261 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | TheScientificWorldJOURNAL |
record_format | MEDLINE/PubMed |
spelling | pubmed-59172612018-06-03 Gene Therapy and Chronic Pain Cope, Doris K. Lariviere, William R. ScientificWorldJournal Review Article Chronic, unremitting pain is perhaps the most common reason that patients seek medical care. In general, conservative techniques, such as medical management, are implemented as first-line therapy. Local anesthesia and lytic procedures, followed by interventional techniques, such as dorsal column stimulation and intrathecal drug delivery systems, are second-line therapies. However, for refractory and severe pain, which is not adequately controlled by other modes of therapy, new emerging options, including molecular or gene therapy, may become more widely utilized as experimental results are translated into clinical options. TheScientificWorldJOURNAL 2006-08-31 /pmc/articles/PMC5917261/ /pubmed/16951899 http://dx.doi.org/10.1100/tsw.2006.197 Text en Copyright © 2006 Doris K. Cope and William R. Lariviere. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Cope, Doris K. Lariviere, William R. Gene Therapy and Chronic Pain |
title | Gene Therapy and Chronic Pain |
title_full | Gene Therapy and Chronic Pain |
title_fullStr | Gene Therapy and Chronic Pain |
title_full_unstemmed | Gene Therapy and Chronic Pain |
title_short | Gene Therapy and Chronic Pain |
title_sort | gene therapy and chronic pain |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917261/ https://www.ncbi.nlm.nih.gov/pubmed/16951899 http://dx.doi.org/10.1100/tsw.2006.197 |
work_keys_str_mv | AT copedorisk genetherapyandchronicpain AT larivierewilliamr genetherapyandchronicpain |